Overview
- Peer-reviewed proof-of-concept data in Vaccines report highly immunogenic responses, including up to roughly eightfold gains over initial versions.
- The method inserts synthetic DNA on plasmids into selected bacteria that are grown and then inactivated to create killed whole-cell vaccines with engineered surface immunogens.
- Designs are refined using tools such as AlphaFold to shape immune responses before manufacturing, streamlining the path from concept to candidate.
- Researchers say candidates could be ready for early testing in about three weeks, a pace intended to beat the 100-day pandemic-response benchmark.
- The team projects production in existing facilities for potentially under $1 per dose with refrigerator-level stability, and UVA’s Licensing & Ventures Group has filed related patents while human trials have not been announced.